ORIC Pharmaceuticals Conference Call Summary Company Overview - **Company**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Focus**: Development of rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for non-small cell lung cancer, in collaboration with Bayer and Johnson & Johnson [4][6] Key Points and Arguments Clinical Data and Pipeline - **Rinzimetostat**: A next-generation PRC2 inhibitor designed for superior potency and a 20-hour clinical half-life, minimizing toxicity [5] - **Phase III Trial**: The first phase III trial, named Himalayas-1, will target post-abiraterone metastatic CRPC, a market worth $3.5 billion annually in the U.S. [6][10] - **Efficacy**: Rinzimetostat shows competitive efficacy with early landmark radiographic progression-free survival (RPFS) rates and a favorable safety profile compared to existing therapies [5][8][10] Competitive Landscape - **Current Therapies**: Existing treatments like enzalutamide and docetaxel show median RPFS of 6-9 months, while rinzimetostat aims for a double-digit RPFS [6][7] - **Comparison with Meverometostat**: Rinzimetostat's early data suggests it may outperform meverometostat in terms of safety and efficacy, with a cleaner safety profile [7][9][36] Safety Profile - **Adverse Events**: Most adverse events for rinzimetostat in combination with darolutamide are grade 1 or 2, with a significantly lower incidence of severe events compared to competitors [9][25][36] - **Patient Population**: The trial population is more heavily pretreated than competitors, with a median baseline PSA of 26 for the 400 mg dose group, indicating a more advanced disease state [24][72] Market Potential - **Addressable Market**: The U.S. market for post-abiraterone mCRPC is estimated at over $3.5 billion, with potential expansion into other prostate cancer indications, increasing the total market to over $10 billion [10][41] - **Physician Insights**: Market research indicates a strong preference for rinzimetostat due to its safety profile, potentially capturing 80% of the PRC2 class market share [49] Future Development - **Additional Trials**: Plans for future phase III trials in other indications, including metastatic castration-sensitive prostate cancer and colorectal cancer, are underway [42][50] - **FDA Engagement**: Regular communication with the FDA is ongoing, with an end-of-phase I meeting planned to finalize the trial design and RP3D selection [65][66] Other Important Content - **Preclinical Data**: Rinzimetostat has shown superior potency in preclinical studies compared to first-generation PRC2 inhibitors, supporting its potential as a best-in-class therapy [11][12] - **Mechanistic Rationale**: The drug's ability to reverse epigenetic reprogramming in prostate cancer cells enhances its therapeutic potential when combined with AR inhibitors [14][15] This summary encapsulates the critical insights from the ORIC Pharmaceuticals conference call, highlighting the company's strategic focus on rinzimetostat and its promising clinical data, competitive positioning, and market potential.

Core Insights - Rinzimetostat 400 mg once daily has been selected as the recommended Phase 3 dose (RP3D) in combination with darolutamide for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in the first half of 2026 [1][4][10] - The 5-month radiographic progression-free survival (rPFS) rate of 84% is consistent with competitor PRC2 inhibitors and significantly better than standard care therapies in mCRPC [1][16] - Rinzimetostat demonstrates a highly differentiated safety profile with a lower frequency and severity of adverse events compared to competitor regimens, with most adverse events being Grade 1 or 2 [1][6][10] Company Updates - ORIC Pharmaceuticals, Inc. is focused on developing treatments that address mechanisms of therapeutic resistance in oncology [3][17] - The company plans to host a conference call and webcast to discuss the rinzimetostat program update [2][15] - The Himalayas-1 trial will enroll approximately 600 patients from over 250 sites in more than 20 countries, randomized to receive either the RP3D of rinzimetostat or physician's choice of an AR inhibitor or chemotherapy [10] Clinical Trial Details - The Phase 1b trial of rinzimetostat in combination with darolutamide involved patients who had previously received a median of two lines of therapy, including abiraterone [5][14] - The recommended Phase 3 dose was selected based on a comprehensive exposure-response analysis, which indicated that the 400 mg dose provided comparable efficacy with a better safety profile than the 600 mg dose [7][8] - Early efficacy data show promising results, with landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, and significant PSA response rates [10][13][16] Market Potential - The annual incidence of mCRPC patients previously treated with abiraterone in the US is approximately 17,000, with an estimated addressable market exceeding $3.5 billion and a total global addressable market of $7 billion [11]

Financial Data and Key Metrics Changes - The fourth quarter net loss was $51 million or $0.97 per share, compared to a net loss of $36.7 million or $0.85 per share for the fourth quarter of 2024 [25] - The full year net loss was $177 million or $3.79 per share, compared to $111.8 million or $2.83 per share for the same period in 2024 [25] - Non-GAAP adjusted net loss for the fourth quarter was $38.4 million or $0.73 per share, compared to $32.3 million or $0.75 per share for the fourth quarter of 2024 [26] - Non-GAAP adjusted net loss for the full year was $150.8 million or $3.22 per share, compared to $101.9 million or $2.58 per share for 2024 [26] - Cash, cash equivalents, and short-term investments were $441.5 million at the end of fiscal year 2025, expected to finance operations through 2027 [30] Business Line Data and Key Metrics Changes - Research and development expenses for the fourth quarter were $37.6 million, up from $33.5 million for the prior year period [27] - R&D expenses for the full year were $145 million, compared to $104.2 million for the prior year [27] - General and administrative expenses for the fourth quarter were $11.6 million, compared to $3 million for the prior year period [28] - G&A expenses for the full year were $27.2 million, compared to $9.1 million for the prior year [28] Market Data and Key Metrics Changes - The total addressable market for gedatolisib in the second-line setting is estimated to be more than $5 billion, with potential peak revenue of up to $2.5 billion annually [18] Company Strategy and Development Direction - The company is preparing for the potential approval and commercialization of gedatolisib, with a PDUFA goal date of July 17, 2026 [5] - The company aims to establish gedatolisib as a new standard of care therapy for patients with HR-positive, HER2-negative advanced breast cancer [5] - The company is engaging with payers and strategic accounts to ensure access to gedatolisib for oncologists and their patients [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the FDA's review of the NDA based on unprecedented efficacy data from the phase III VIKTORIA-1 clinical trial [6] - The company believes that the positive results from the PIK3CA wild-type cohort will position gedatolisib favorably in the market [14] - Management highlighted the importance of the safety profile of gedatolisib, which does not induce clinically relevant hypoglycemia [11][70] Other Important Information - The company has completed enrollment of the PIK3CA mutant cohort of the phase III VIKTORIA-1 trial and expects to announce results in the second quarter [7] - The company is also evaluating gedatolisib in combination with darolutamide for men with metastatic castration-resistant prostate cancer [15] Q&A Session Summary Question: Status update on the mutant data - Management could not comment on the database lock status [33] Question: Details on the disclosure of mutant data - Management indicated that top-line data will be provided in a press release, with details at a medical conference [34] Question: Feedback from physicians on launch segments - Management stated that the sales force will reach out generally to doctors to help them understand the benefits of gedatolisib [43] Question: Will physicians use it off-label for mutants? - Management confirmed that there have been no discussions with doctors about off-label use [44] Question: Details on the top-line release of median data - Management confirmed that the release will include a statement regarding the achievement of statistical significance [48] Question: Key gating factor for frontline endocrine-sensitive trial - The key gating factor is completing the safety run-in [58] Question: Challenges in getting patients for infusions - Management believes that efficacy is the most important factor for physicians and does not expect significant patient pushback on IV administration [61] Question: Commercial advantages of having a label across metastatic breast cancer subtypes - Management aims to simplify decision-making for physicians by providing a biomarker-agnostic alternative [66] Question: Learnings from the launch of inavolisib - Management noted that gedatolisib does not induce significant glycemic disruption, allowing broader patient treatment [70] Question: European commercial strategy for gedatolisib - Management plans to submit a supplemental NDA after initial approval and explore partnerships for launching in Europe [78]

Financial Data and Key Metrics Changes - The fourth quarter net loss was $51 million or $0.97 per share, compared to a net loss of $36.7 million or $0.85 per share for the fourth quarter of 2024 [25] - The full year net loss was $177 million or $3.79 per share, compared to $111.8 million or $2.83 per share for the same period in 2024 [25] - Non-GAAP adjusted net loss for the fourth quarter was $38.4 million or $0.73 per share, compared to $32.3 million or $0.75 per share for the fourth quarter of 2024 [26] - Non-GAAP adjusted net loss for the full year was $150.8 million or $3.22 per share, compared to $101.9 million or $2.58 per share for 2024 [26] - Cash, cash equivalents, and short-term investments were $441.5 million at the end of fiscal year 2025, expected to finance operations through 2027 [30] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses for the fourth quarter were $37.6 million, up from $33.5 million for the prior year [27] - R&D expenses for the full year were $145 million, compared to $104.2 million for the prior year [27] - General and administrative (G&A) expenses for the fourth quarter were $11.6 million, compared to $3 million for the prior year [28] - G&A expenses for the full year were $27.2 million, compared to $9.1 million for the prior year [28] Market Data and Key Metrics Changes - The total addressable market for gedatolisib in the second-line setting is estimated to be more than $5 billion, with potential peak revenue of up to $2.5 billion annually [18] Company Strategy and Development Direction - The company is preparing for the potential approval and commercialization of gedatolisib, aiming to establish it as a new standard of care for HR-positive, HER2-negative advanced breast cancer [5][19] - The company has engaged extensively with payers and strategic accounts to ensure access to gedatolisib upon approval [16][90] - The company plans to conduct a supplemental NDA submission for the mutant cohort following initial approval for gedatolisib [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the FDA's review of the NDA for gedatolisib, citing unprecedented efficacy data from clinical trials [6][17] - The company believes that gedatolisib's unique mechanism of action and safety profile position it well in the market [19][92] - Management highlighted the importance of efficacy as the primary factor influencing physician and patient decisions regarding treatment [62] Other Important Information - The company completed enrollment of the PIK3CA mutant cohort of the phase III VIKTORIA-1 trial and expects to announce results in the second quarter of 2026 [7] - Safety results from clinical trials indicated that gedatolisib was generally well-tolerated, with low rates of treatment-related adverse events [10][11] Q&A Session Summary Question: Status update on the mutant data - Management could not comment on the database lock status for the mutant data [33] Question: Details on the disclosure of mutant data - Management indicated that top-line data will be provided in a press release, with further details at a medical conference [34] Question: Feedback from physicians on treatment segments - Management stated that the sales force will reach out to doctors generally to explain how gedatolisib offers improvements over current alternatives [43] Question: Will physicians use gedatolisib off-label for mutants? - Management confirmed that there have been no discussions with doctors regarding off-label use [44] Question: Details on the top-line release of median data - Management stated that the release will include a statement regarding the achievement of statistical significance [48] Question: Key gating factor for frontline endocrine-sensitive trial - The key gating factor is completing the safety run-in for the trial [58] Question: Challenges in getting patients for infusions - Management believes that efficacy will be the most important factor for physicians and patients, and they do not expect significant pushback on IV administration [61] Question: Commercial advantages of having a label across metastatic breast cancer subtypes - Management aims to simplify decision-making for physicians by providing a biomarker-agnostic alternative [66] Question: Learnings from the launch of inavolisib - Management noted that gedatolisib does not induce significant glycemic disruption, allowing broader patient eligibility [70] Question: European commercial strategy for gedatolisib - Management plans to explore partnerships for launching gedatolisib in Europe while proceeding with regulatory activities [78]

Summary of Celcuity Conference Call Company Overview - **Company**: Celcuity (NasdaqCM:CELC) - **Focus**: Development of a platform to isolate and quantify the activity of live patient tumor cells to identify responsive patients for targeted therapies, particularly in the PI3K space with the drug gedatolisib, a pan-PI3K/mTOR inhibitor [7][8] Key Points and Arguments Clinical Development - **Phase 3 Studies**: Completed one phase three study and has another upcoming report in the second line study for breast cancer, along with a first line study in progress [7][8] - **Efficacy of Gedatolisib**: - Demonstrated unprecedented efficacy in the second line setting with a median progression-free survival (PFS) of 9.3 months compared to 2 months for fulvestrant, with a hazard ratio of 0.24 [34] - Early phase data showed a median PFS of 14.5 months in a cohort of patients with PIK3CA mutations, indicating potential for significant clinical relevance [36][37] - **Targeting the PAM Pathway**: Gedatolisib is believed to effectively target the PAM pathway, which has been suboptimally targeted by other drugs, leading to modest efficacy in a subset of patients [14][15] Market Landscape - **Current Treatments**: The current standard of care for HR-positive breast cancer patients is yielding limited results, with existing therapies like fulvestrant and AI not showing significant improvements [25][26] - **Impact of Competitors**: Recent failures of other oral SERDs in clinical trials provide clarity on treatment regimens and highlight the potential for gedatolisib to fill the gap in treatment efficacy [27][28] Future Studies and Expectations - **Upcoming Data**: Expected to report data on the mutant population by the end of the current quarter or next quarter, with a focus on achieving statistically significant results [36][37] - **Frontline Study**: A phase 3 study targeting HR-positive, treatment-naive patients is in progress, with a safety run-in evaluating gedatolisib combined with ribociclib [55][57] Commercial Strategy - **Sales Force Preparation**: The company is preparing to build a sales force, targeting around 90 representatives, to effectively reach healthcare providers [63][64] - **Market Access**: The intravenous formulation of gedatolisib is expected to facilitate easier reimbursement pathways compared to oral drugs, enhancing market access [67] International Expansion - **Regulatory Strategy**: Plans to submit a Marketing Authorization Application (MAA) in Europe following the mutation data submission to the FDA, with a focus on major markets including the EU and Japan [81][82] Additional Insights - **Prostate Cancer Program**: Gedatolisib is also being evaluated in combination with darolutamide for prostate cancer, showing promising early results [70][71] - **Potential for Other Tumor Types**: There is interest in exploring gedatolisib's efficacy in endometrial cancer, although the landscape is complicated by the use of PD-1 drugs [74] Intellectual Property - **Patent Exclusivity**: The company expects patent term exclusivity through 2042 based on dosing patents, which are critical for optimizing treatment outcomes [76][77] This summary encapsulates the key points discussed during the Celcuity conference call, highlighting the company's strategic direction, clinical developments, and market positioning.

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer [2][3] Key Programs 1. **Rinzimetostat (ORIC-944)**: - Allosteric PRC2 inhibitor targeting prostate cancer in combination with AR inhibitors (apalutamide and darolutamide) [2][3] - Phase III study expected to start in the first half of 2026 [3][4] - Early clinical data shows promising PSA response rates and favorable safety profile compared to Pfizer's data [5][17] 2. **Enosertinib**: - EGFR inhibitor with high potency on exon 20 and PAK mutations [3][43] - Demonstrated 100% overall response rate in patients with measurable disease, including those with untreated brain metastases [43] Market Opportunity - **Prostate Cancer**: - Large patient population with significant unmet needs; over $11 billion in sales for ARPi inhibitors last year [23][24] - Potential to reverse resistance to current therapies and extend treatment duration [24][25] - **Lung Cancer**: - High prevalence of CNS metastases in lung cancer patients, making CNS activity a critical differentiator for enosertinib [43][44] Competitive Landscape - **Rinzimetostat vs. Mevrometostat**: - Rinzimetostat is positioned as a potentially best-in-class PRC2 inhibitor with better drug properties, including solubility and half-life [11][12] - Early data suggests lower rates of gastrointestinal and hematological toxicities compared to competitors [17] - **Enosertinib's Differentiation**: - Focus on CNS activity and less off-target toxicities compared to competitors [43][44] Upcoming Milestones - **Rinzimetostat**: - Q1 update with data from 20-25 patients expected, focusing on PSA50, PSA90, safety, and tolerability [38][39] - Phase III study initiation in the first half of 2026 [3][38] - **Enosertinib**: - Continued evaluation of monotherapy and combination strategies, with updates expected in the second half of 2026 [48][49] Investor Considerations - The stock's performance is closely tied to the outcomes of the MEVPRO-1 study and the company's own data releases [53][56] - Rinzimetostat is viewed as a potential blockbuster if it demonstrates differentiation in safety and efficacy [58] Conclusion Oric Pharmaceuticals is strategically positioned in the oncology space with promising drug candidates targeting significant unmet needs in prostate and lung cancers. The upcoming data releases and competitive positioning will be critical for investor confidence and stock performance moving forward.

Summary of ORIC Pharmaceuticals Conference Call Company Overview - ORIC Pharmaceuticals is a clinical-stage oncology company focused on overcoming resistance in cancer, particularly in prostate, lung, and breast cancer [2][3] Key Programs - **ORIC-944**: An allosteric PRC2 inhibitor for prostate cancer, expected to start a Phase III study in the first half of 2026 [2][7] - **Enozertinib (ORIC-114)**: A selective brain-penetrant EGFR inhibitor targeting exon 20 and PACC mutations, with updates expected in the second half of 2026 [3][34] Competitive Landscape - Pfizer's **Mevrometostat** showed a PFS of 14.3 months in prostate cancer, which ORIC aims to match or exceed with their own data [5][6] - ORIC's early data showed a PSA 50 response of 40% compared to Pfizer's 34%, indicating a potentially better efficacy profile [6][10] Safety and Efficacy - ORIC believes that safety is a significant differentiator in prostate cancer treatments, with their program showing fewer adverse events compared to Pfizer's [10][13] - The company does not believe it needs to be differentiated in efficacy due to the large market and unmet needs in prostate cancer [11][12] Market Opportunity - The metastatic CRPC market is estimated to have 30,000-40,000 patients annually in the US, with a significant portion having prior exposure to AR inhibitors [25][26] - The potential market opportunity for ORIC's treatments in the post-abi setting is estimated at $3.5 billion [28] Financial Position - ORIC raised $244 million in mid-2025, providing a cash runway into the second half of 2028, which covers the costs of the first Phase III study [24][46] - The company is well-capitalized and does not require a corporate partner to initiate the first Phase III study [22][23] Future Plans - An update on dose optimization data for ORIC-944 is expected in Q1 2026, with a focus on PSA responses and safety [15][17] - ORIC plans to evaluate which AR inhibitor (apalutamide or darolutamide) to use in the Phase III study based on data from the Q1 update [19][20] Enozertinib Development - ORIC plans to continue investing in enozertinib, with a focus on CNS activity, which is a significant unmet need in lung cancer [35][36] - The company aims to differentiate itself in the EGFR market, which is competitive and requires best-in-class inhibitors [39][40] Conclusion - ORIC Pharmaceuticals is positioned to capitalize on significant market opportunities in oncology, with a strong focus on safety and efficacy in its drug development programs. The company is financially stable and prepared to advance its clinical trials without immediate need for external partnerships.

Core Insights - Orion anticipates significant growth for darolutamide, a prostate cancer medication co-developed with Bayer [1] Company Summary - Orion is focused on the development and commercialization of darolutamide, indicating a strong commitment to the oncology market [1] Industry Summary - The prostate cancer treatment market is expected to expand, with darolutamide positioned as a key player due to its co-development with Bayer [1]

Core Insights - ORIC Pharmaceuticals announced additional efficacy and safety data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC) [1][2] Efficacy Data - The trial demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate among patients [6] - Rapid and deep circulating tumor DNA (ctDNA) reductions were observed in 76% of patients, with 59% achieving ctDNA clearance, indicating potential long-term treatment benefits [1][7] - PSA responses and ctDNA reductions were consistent across all ORIC-944 dose levels and in combination with both apalutamide and darolutamide [4][5] Safety Profile - The combination of ORIC-944 with apalutamide or darolutamide showed a safety profile compatible with long-term dosing, with most adverse events being Grade 1 or 2 [8] - As of the cutoff date, only one patient experienced a Grade 3 treatment-related adverse event, with no Grade 4 or 5 adverse events reported [8] Next Steps - ORIC has selected provisional recommended Phase 2 doses for ORIC-944 to be tested in combination with darolutamide and apalutamide, with ongoing enrollment in the dose optimization portion of the trial [9] - Preliminary dose optimization data is expected to be announced in Q1 2026, ahead of initiating the first global Phase 3 registrational trial in mCRPC in the first half of 2026 [2][9] Company Overview - ORIC Pharmaceuticals is focused on developing treatments that address mechanisms of therapeutic resistance in cancer, with ORIC-944 being an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) [11]

Financial Data and Key Metrics Changes - The company's net loss for Q3 2025 was $43.8 million, or $0.92 per share, compared to a net loss of $29.8 million, or $0.70 per share for Q3 2024 [19] - Non-GAAP adjusted net loss was $37.2 million, or $0.78 per share for Q3 2025, compared to a non-GAAP adjusted net loss of $27.6 million, or $0.65 per share for Q3 2024 [19] - Research and development expenses increased to $34.9 million for Q3 2025 from $27.6 million in Q3 2024, with a significant portion attributed to increased employee and consulting expenses [19][20] - General and administrative expenses rose to $7.9 million for Q3 2025 from $2.5 million in Q3 2024, primarily due to increased employee and consulting expenses [20] Business Line Data and Key Metrics Changes - The company achieved significant clinical and regulatory milestones, including the release of positive data from the PIK3CA wild-type cohort of the phase III VIKTORIA-1 study [4][5] - The median progression-free survival (PFS) for the gedatolisib triplet was reported at 9.3 months, compared to 2 months for fulvestrant, indicating a 7.3-month improvement [7] - The objective response rate for the gedatolisib triplet was 32%, with a median duration of response of 17.5 months, while the doublet showed an objective response rate of 28% and a median duration of response of 12.0 months [9][10] Market Data and Key Metrics Changes - The total addressable market for gedatolisib in the second-line setting is estimated to be between $5 billion and $6 billion, with potential peak revenues of $2.5 billion to $3 billion [17][18] - The company estimates there are approximately 37,000 patients in the U.S. with HR positive, HER2 negative, advanced breast cancer who have progressed after treatment with a CDK4/6 inhibitor [17] Company Strategy and Development Direction - The company is preparing for a potential launch of gedatolisib, having ramped up efforts following the positive data release [15] - The strategic launch plan includes building the organization and internal systems required to operate as a commercial stage company [15] - The company aims to establish gedatolisib as the new standard of care in the second-line setting for HR positive, HER2 negative, advanced breast cancer [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for gedatolisib to address critical needs in the second-line space, highlighting its unique mechanism of action and favorable safety and efficacy profile [18] - The company expects to complete the NDA submission for gedatolisib by the end of Q4 2025 [26] - Management noted that the positive interim overall survival data could support the drug's approval process [38] Other Important Information - The company completed concurrent offerings resulting in net proceeds of approximately $287 million, which will support commercial launch preparations and other strategic initiatives [21][22] - The company ended the quarter with approximately $455 million in cash, cash equivalents, and short-term investments [20] Q&A Session Summary Question: Plans for additional data at the San Antonio Breast Cancer Symposium - The company plans to present additional subgroup analyses and efficacy data at the conference [24] Question: Impact of second-line data on enrollment in VIKTORIA II - Enrollment is on track, and investigators are excited about the results, which may positively impact visibility and credibility [24] Question: Real-time oncology review submission process - The submission for the wild-type cohort will be separate from the mutant submission, with potential for a real-time oncology review for the mutant data depending on the results [25][27] Question: Duration of therapy and pricing strategy - The company is analyzing the duration of therapy and pricing strategy, with benchmarks around $25,000 for similar therapeutics [28][29] Question: Plans for commercialization outside the U.S. - The company plans to find partners for commercialization outside the U.S. and is preparing for regulatory submissions in Europe and Japan [31] Question: Overall survival trends and regulatory implications - The interim overall survival analysis showed a favorable trend, which could support the drug's approval process [38]